AI Terminal
NUFORMIX PLC
Board/Management Information • May 25, 2023
4941_rns_2023-05-25_725207da-6150-4157-8a7d-fcdaeab80dcc.html
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5717A
Nuformix PLC
25 May 2023
25 May 2023
Nuformix plc
("Nuformix" or the "Company")
Change of Auditor
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Kreston Reeves LLP ("Kreston Reeves") as auditor to the Company. The appointment of Kreston Reeves will be subject to approval by shareholders at the next Annual General Meeting of the Company.
Enquiries:
| Nuformix plc | |
| Dr Dan Gooding, Executive Director | Via IFC Advisory |
| Stanford Capital Partners Limited | |
| Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
| John Howes (Corporate Broking) | +44 (0) 20 3650 3652 |
| IFC Advisory Limited | |
| Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 [email protected] |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPEAXSLASSDEFA